{
  "openalex_id": "W2908807534",
  "doi": "https://doi.org/10.1177/2054358118821945",
  "title": "Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey",
  "abstract": "Nonvalvular atrial fibrillation (NVAF) is an independent risk factor for ischemic stroke and is common in chronic kidney disease (CKD) and dialysis patients. The use of oral anticoagulation to prevent stroke and systemic embolism in the setting of kidney disease is controversial. Novel alternatives to vitamin K antagonists include left atrial appendage occlusion devices (LAAOD) and apixaban.We sought to elicit Canadian nephrologist views regarding stroke and systemic embolism prevention therapies in CKD and dialysis patients with NVAF.Survey.Online via https://www.surveymonkey.com.Canadian Society of Nephrology members actively treating adult dialysis patients with NVAF.Management questions were asked with response options consisting of a Likert scale ranging from 1 to 8 (with 1 being definitely would not and 8 being definitely would).We randomly allocated each respondent to 2 of 4 cases that varied by stroke and bleeding risks (using varying CHADS2 and HASBLED scores, respectively).There were 91 responses (36.3% response rate) from mostly university (83.5%) and also community with university affiliation (12.1%) and community (4.4%) nephrologists. Warfarin was more likely to be recommended in individuals at high stroke risk and low bleeding risk (mean = 5.47, 95% confidence interval = 4.87-6.07) and less likely to be recommended in individuals at moderate stroke risk and high bleeding risk (mean = 2.89, 95% confidence interval = 2.37-3.41). The likelihood of recommending LAAOD did not vary by stroke or bleeding risks (means ranging from 3.92-4.90). Apixaban was not likely to be recommended in any case (means ranging from 2.60-3.50). However, nephrologists felt there was equipoise regarding anticoagulation strategies allowing participation in appropriate randomized controlled trials (RCTs).The survey only involved nephrologists and only 4 cases with dichotomized risk categories were presented instead of complete range of stroke and bleeding risk combinations. As with any survey, there was the potential for responder bias and treatment decisions are not anchored directly to patient management.Nephrologists caring for patients with kidney disease appear willing to include patients in clinical trials examining alternatives to warfarin for stroke and systemic embolism prevention for NVAF in the setting of kidney disease.La fibrillation auriculaire non valvulaire (FANV) est un facteur de risque indépendant de l’accident vasculaire cérébral (AVC) ischémique et est fréquente chez les patients atteints d’insuffisance rénale chronique (IRC) et chez les patients dialysés. L’administration orale d’anticoagulants en prévention des AVC et des embolies systémiques en contexte de néphropathie est controversée. Les nouvelles solutions pour remplacer les antagonistes de la vitamine K incluent des dispositifs d’occlusion de l’appendice auriculaire (LAAOD) et l’apixaban.Nous souhaitions sonder les néphrologues canadiens au sujet des traitements préventifs de l’embolie systémique et de l’AVC chez les patients atteints d’IRC et dialysés présentant une FANV.Un sondage.Un sondage en ligne au https://www.surveymonkey.com.Les membres de la Société canadienne de néphrologie traitant des adultes dialysés présentant de la FANV.Des questions concernant la prise en charge des patients ont été posées avec un choix de réponses sous la forme d’une échelle de Likert allant de 1 à 8, où 1 signifiait « certainement pas » et 8 « très certainement ».De façon aléatoire, nous avons assigné à chaque répondant de deux à quatre cas variant en sévérité pour les risques d’AVC et d’hémorragie (en fonction des scores CHADS2 et HASBLED respectivement).Nous avons obtenu 91 réponses (taux de réponse de 36,3 %) provenant principalement de néphrologues pratiquant en milieu universitaire (83,5 %), mais également d’un milieu communautaire (4,4 %) ou d’un milieu communautaire affilié à une université (12,1 %). La warfarine s’est avérée plus susceptible d’être recommandée pour les sujets à haut risque d’AVC et présentant de faibles risques d’hémorragie (moyenne : 5,47; IC 95 % : 4,87-6,07). Elle était moins susceptible d’être recommandée aux patients présentant un risque moyennement élevé d’AVC et un haut risque d’hémorragie (moyenne : 2,89; IC 95 % : 2,37-3,41). La probabilité de recommander les LAAOD n’a pas varié en fonction du risque d’AVC ou d’hémorragie (moyennes variant entre 3,92 et 4,90). Dans tous les cas, l’apixaban n’était pas susceptible d’être recommandé (moyennes variant entre 2,60 et 3,50). De leur côté, les néphrologues ont estimé qu’il existait un équilibre entre les différentes stratégies d’anticoagulation, ce qui permettait la participation aux essais contrôlés à répartition aléatoire appropriés.Le sondage ne s’adressait qu’aux néphrologues, et seuls quatre cas avec des catégories de risque dichotomiques ont été présentés plutôt qu’une gamme complète de risques combinés d’AVC et d’hémorragie. En outre, les décisions relatives au traitement n’étaient pas directement liées à la prise en charge de patients. Enfin, comme pour tout sondage, celui-ci comporte un potentiel biais de réponse.Les néphrologues seraient disposés à inclure leurs patients dans des essais cliniques portant sur les solutions de rechange à la warfarine en contexte de néphropathie pour prévenir les AVC et les embolies systémiques en présence de FANV.",
  "authors": [
    {
      "display_name": "David Collister",
      "id": "A5071907350",
      "orcid": "https://orcid.org/0000-0002-2323-6521",
      "institutions": [
        {
          "id": "I2802834092",
          "display_name": "Population Health Research Institute",
          "country_code": "CA",
          "type": "healthcare"
        },
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        },
        {
          "id": "I59293822",
          "display_name": "St. Joseph’s Healthcare Hamilton",
          "country_code": "CA",
          "type": "healthcare"
        }
      ],
      "is_corresponding": true,
      "raw_author_name": "David Collister"
    },
    {
      "display_name": "Jeff S. Healey",
      "id": "A5010703194",
      "orcid": "https://orcid.org/0000-0003-1216-7580",
      "institutions": [
        {
          "id": "I2802834092",
          "display_name": "Population Health Research Institute",
          "country_code": "CA",
          "type": "healthcare"
        },
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jeff S. Healey"
    },
    {
      "display_name": "David Conen",
      "id": "A5068858051",
      "orcid": "https://orcid.org/0000-0002-2459-5251",
      "institutions": [
        {
          "id": "I2802834092",
          "display_name": "Population Health Research Institute",
          "country_code": "CA",
          "type": "healthcare"
        },
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "David Conen"
    },
    {
      "display_name": "K. Scott Brimble",
      "id": "A5038041339",
      "orcid": "https://orcid.org/0000-0001-8852-0542",
      "institutions": [
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "K. Scott Brimble"
    },
    {
      "display_name": "Claudio Rigatto",
      "id": "A5089508740",
      "orcid": "https://orcid.org/0000-0002-8306-8072",
      "institutions": [
        {
          "id": "I46247651",
          "display_name": "University of Manitoba",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Claudio Rigatto"
    },
    {
      "display_name": "Ziv Harel",
      "id": "A5056937094",
      "orcid": "https://orcid.org/0000-0002-8618-4538",
      "institutions": [
        {
          "id": "I185261750",
          "display_name": "University of Toronto",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Ziv Harel"
    },
    {
      "display_name": "Manish M. Sood",
      "id": "A5036326268",
      "orcid": "https://orcid.org/0000-0002-9146-2344",
      "institutions": [
        {
          "id": "I153718931",
          "display_name": "University of Ottawa",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Manish M. Sood"
    },
    {
      "display_name": "Michael Walsh",
      "id": "A5013696488",
      "orcid": "https://orcid.org/0000-0001-8292-2014",
      "institutions": [
        {
          "id": "I98251732",
          "display_name": "McMaster University",
          "country_code": "CA",
          "type": "funder"
        },
        {
          "id": "I2802834092",
          "display_name": "Population Health Research Institute",
          "country_code": "CA",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Michael Walsh"
    }
  ],
  "publication_year": 2019,
  "publication_date": "2019-01-01",
  "type": "article",
  "cited_by_count": 4,
  "is_retracted": false,
  "is_paratext": false,
  "language": "fr",
  "source": {
    "id": "S2764509245",
    "display_name": "Canadian Journal of Kidney Health and Disease",
    "issn_l": "2054-3581",
    "issn": [
      "2054-3581"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320017"
  },
  "volume": "6",
  "issue": null,
  "first_page": null,
  "last_page": null,
  "open_access": {
    "is_oa": true,
    "oa_status": "gold",
    "oa_url": "https://journals.sagepub.com/doi/pdf/10.1177/2054358118821945",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.9371532
    },
    {
      "id": "C2780638905",
      "display_name": "Apixaban",
      "level": 5,
      "score": 0.8513433
    },
    {
      "id": "C2779161974",
      "display_name": "Atrial fibrillation",
      "level": 2,
      "score": 0.80569196
    },
    {
      "id": "C2780645631",
      "display_name": "Stroke (engine)",
      "level": 2,
      "score": 0.7252129
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.7079291
    },
    {
      "id": "C54847362",
      "display_name": "Nephrology",
      "level": 2,
      "score": 0.6670115
    },
    {
      "id": "C2778661090",
      "display_name": "Rivaroxaban",
      "level": 4,
      "score": 0.6076054
    },
    {
      "id": "C2778653478",
      "display_name": "Kidney disease",
      "level": 2,
      "score": 0.6013528
    },
    {
      "id": "C2779978075",
      "display_name": "Dialysis",
      "level": 2,
      "score": 0.5596732
    },
    {
      "id": "C2776301958",
      "display_name": "Warfarin",
      "level": 3,
      "score": 0.5093769
    },
    {
      "id": "C2777185221",
      "display_name": "Embolism",
      "level": 2,
      "score": 0.4831583
    },
    {
      "id": "C164705383",
      "display_name": "Cardiology",
      "level": 1,
      "score": 0.47826803
    },
    {
      "id": "C177713679",
      "display_name": "Intensive care medicine",
      "level": 1,
      "score": 0.36841103
    },
    {
      "id": "C78519656",
      "display_name": "Mechanical engineering",
      "level": 1,
      "score": 0.0
    },
    {
      "id": "C127413603",
      "display_name": "Engineering",
      "level": 0,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T10065",
      "display_name": "Atrial Fibrillation Management and Outcomes",
      "score": 0.9999
    },
    {
      "id": "T10285",
      "display_name": "Venous Thromboembolism Diagnosis and Management",
      "score": 0.9935
    },
    {
      "id": "T10227",
      "display_name": "Acute Ischemic Stroke Management",
      "score": 0.9915
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1177/2054358118821945",
  "pdf_url": "https://journals.sagepub.com/doi/pdf/10.1177/2054358118821945",
  "retrieved_date": "2025-07-30T14:28:20.189668",
  "source_database": "OpenAlex"
}